Effects of telmisartan on endothelial progenitor cells and high sensitive C-reactive protein in patients with unstable angina pectoris

doi:10.3969/j.issn.2095-4344.2014.29.019

Abstract

Abstract:

BACKGROUND: Atherosclerotic plaque is chronic low-level inflammation in human body. Telmisartan can lower blood pressure, protect the target organs and inhibit inflammation, also partially activate peroxisome proliferator-activated receptor γ, increase the number of progenitor cells, and inhibit inflammation of vascular wall cells.

OBJECTIVE: To observe the effects of telmisartan on endothelial progenitor cells and high-sensitivity C-reactive protein in peripheral blood of patients with unstable angina pectoris.

METHODS: 200 patients with unstable angina pectoris who consulted the doctors of the First People’s Hospital of Neijiang from January 2012 to December 2013 were randomly divided into contrast group and telmisartan group, with 100 patients in each group. The general clinical data of each patient was collected. Peripheral venous blood was taken before treatment and 4, 8 weeks after treatment. Endothelial progenitor cells and high-sensitivity C-reactive protein level were detected.

RESULTS AND CONCLUSION: At 4 and 8 weeks after treatment, the percentage of endothelial progenitor cells in telmisartan group was significantly higher than those before treatment and that of contrast group (P < 0.05). At 4 and 8 weeks after treatment, the high-sensitivity C-reactive protein level was decreased significantly in telmisartan group compared with before treatment. The telmisartan group had a significantly lower level than the contrast group (P < 0.05). Telmisartan can promote the proliferation of endothelial progenitor cells and restoration of damaged vessels. It can also reduce high-sensitivity C-reactive protein level and inhibit the inflammatory reaction.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: unstable angina pectoris, telmisartan, endothelial progenitor cells, high sensitive C-reactivity protein, treatment

CLC Number:

R318

Ni Wei. Effects of telmisartan on endothelial progenitor cells and high sensitive C-reactive protein in patients with unstable angina pectoris[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(29): 4701-4705.

Figures/Tables 2

References

[1] 李雪艳,吴新华.炎症在急性冠脉综合征中的作用及意义研究[J].实用心脑肺血管病杂志,2012,20(5):927-928.
[2] 熊军,陈铭,柳文菊,等.冠状动脉粥样硬化型心脏病患者检测高敏C-反应蛋白的意义[J].国际检验医学杂志,2011,32(4):483-484.
[3] Luo P, Li L, Wang LX, et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genet Mol Res. 2014;13(2):2377-2384.
[4] Ridker PM, Burntng JE, Shih J, et al. Prospective study of C reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8): 731-736.
[5] Tataru MC, Heinrich J, Jun ker R, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J. 2000;21(12): 1000-1008.
[6] 白小涓.内皮祖细胞在动脉粥样硬化易损斑块中的作用[J].中国动脉硬化杂志,2011,19(7):543-546.
[7] Kawamoto A, Gwon HC, Lwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103(5):634-637.
[8] 郭长磊,李红军.内皮祖细胞与冠状动脉病变严重程度的分析[J].中国现代药物应用,2010,4(20):53-54.
[9] 林泽鹏,金光临,张志伟.替米沙坦对老年高血压不稳定型心绞痛患者脂联素及C-反应蛋白的影响[J].中华老年医学杂志, 2005, 24(8):631-633.
[10] 郭完计,李晶,郭倩云,等.替米沙坦对不稳定型心绞痛患者血清hs-CRP、MMP-9和AngⅡ水平的影响[J].中国循证心血管医学杂志,2012,4(1):20-22.
[11] 马晶晶,章涛.PPARγ功能与疾病关系研究进展[J].中国药理学通报,2012,28(5):601-604.
[12] 王静,徐萍,侯彦强,等.PPARγ激动剂对单核细胞炎症反应的调控作用[J].上海交通大学学报(医学版),2012,32(7):861-865.
[13] 郭倩云,郭完计,李晶,等.替米沙坦对老年不稳定型心绞痛患者血清hs-CRP、MMP-9和AngⅡ水平的影响[J].中西医结合心脑血管病杂志,2012,10(7):775-777.
[14] 杨大春,马双陶,唐兵,等.替米沙坦对高血压伴不稳定型心绞痛患者单核细胞中PPARs表达的影响[J].中国药理学通报, 2010, 26(7): 882-885.
[15] 郑虹,米树华,杨红霞,等.替米沙坦对老年原发性高血压伴代谢综合征血尿酸和超敏C-反应蛋白的影响[J].心肺血管病杂志, 2011, 30(2):107-109.
[16] 董西刚,孙林,张戈.易损斑块的血清标记物研究进展[J].中国动脉硬化杂志,2012,20(6):568-572.
[17] Michiels C. Endothelial cell functions. J Cell Physio. 2003; 196(3):430-443.
[18] Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights from esperimental medels. Iint J Exp Pathol. 2000;81(2):63-88.
[19] 印章.替米沙坦对不稳定型心绞痛患者内皮祖细胞和高敏C-反应蛋白的作用[J].临床荟萃,2013,28(8):858-860.
[20] 杨军,张桂芳.血管紧张素Ⅱ受体拮抗剂特征及应用进展[J].中国当代医药,2011,18(23):22-23.
[21] Siragusa M, Sessa WC. Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. Arterioscler Thromb Vasc Biol. 2013;33(8): 1852-1860.
[22] 曹政,杨勇,吴瑞霞,等.替米沙坦通过磷脂酰肌醇-3-激酶/丝苏氨酸蛋白激酶途径改善内皮祖细胞的功能活性[J].中国动脉硬化杂志,2012,20(12):1083-1087.
[23] Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization:a novel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells. Circulation. 2002;105(25): 3017-3024.
[24] Yang N. Apolipoprotein A-I mimetic peptidereverse D-4F improves the biological functions of mouse bone marrow derived late EPCs via PI3K/AKT/eNOS pathway. Mol Cell Biol Chem. 2013;377(1-2):229-236.
[25] Mills NL, Tura O, Padfield GJ, et al. Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart. 2009;95(14):2003-2008.
[26] Klinghammer L, Urschel K, Cichal I, et al. Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis-Influence on IP-10, TNF-α and MCP-1. Cytokine. 2013;62(2):290-296.
[27] 于海波,韩雅玲,王祖禄,等.替米沙坦降压疗效的临床研究[J].高血压杂志,2004,12(6):515-518.
[28] 李萍,田毅.急性冠状动脉综合征患者治疗前后血浆炎症因子水平的变化及意义[J].中国药物与临床,2012,12(9):1176-1177.
[29] 刘继烈.瑞舒伐他汀对不稳定型心绞痛患者C-反应蛋白的影响[J].实用心脑肺血管病杂志,2012,20(5):774-775.
[30] 贺芬芬,李哈妮,孙芳玲,等.药物稳定动脉粥样硬化易损斑块的研究进展[J].中国康复理论与实践,2012,18(10):934-938.